Department of Urology, Clinica Urologica I, Azienda Ospedaliera Careggi, Università di Firenze, Viale San Luca, 50134, Florence, Italy.
Department of Haematology, University of Florence, Careggi Hospital, Florence, Italy.
Int Urol Nephrol. 2019 Oct;51(10):1715-1720. doi: 10.1007/s11255-019-02223-0. Epub 2019 Jul 18.
Haemorrhagic cystitis (HC) after allogeneic transplantation (HSCT) is a condition characterized by diffuse inflammation and bleeding from the bladder mucosa. Treatment of HC is not standardized and clinical Guidelines are elusive. The aim of this study was to evaluate the safety and efficacy of intravesical treatment with platelet-rich plasma (PRP) in patients with HC after allogenic HSCT.
Data from ten consecutive patients with BK virus-induced HC between 2013 and 2017 were collected. HC was classified into four grades. Inclusion criteria were (a) grade 3 or 4 BKV-induced HC after allogenic HSCT; (b) HC refractory to conservative therapy. All patients underwent transurethral cystoscopy and PRP treatment under general anaesthesia.
Mean patients' age was 33.6 years. Four patients (40%) presented a grade 3 BKV-induced HC and six patients (60%) a grade 4. No intraoperative complications occurred. Postoperative complications were recorded in six patients: three patients required blood transfusion while three patients endovenous antibiotic therapy. Median time to catheter removal was 6 days (IQR 2-10). Median length of hospitalization was 35 days (IQR 6-73). At 30 days after surgery, a three-way catheter was repositioned in one patient for grade 4 haematuria, six patients had a complete response, and three a partial response.
Our preliminary experience suggests that intravesical administration of PRP should be considered as a feasible and safe option for the treatment of BK-induced HC after HSCT. Future studies are needed to assess its potential value in other forms of haemorrhagic cystitis.
异基因移植(HSCT)后出血性膀胱炎(HC)是一种以膀胱黏膜弥漫性炎症和出血为特征的疾病。HC 的治疗尚未标准化,临床指南也难以确定。本研究旨在评估富含血小板的血浆(PRP)腔内治疗异基因 HSCT 后 HC 患者的安全性和疗效。
收集了 2013 年至 2017 年间 10 例连续接受 BK 病毒诱导的 HC 的患者的数据。将 HC 分为四级。纳入标准为:(a)异基因 HSCT 后 3 级或 4 级 BKV 诱导的 HC;(b)HC 对保守治疗无效。所有患者均在全身麻醉下接受经尿道膀胱镜检查和 PRP 治疗。
患者平均年龄为 33.6 岁。4 例(40%)患者出现 3 级 BKV 诱导的 HC,6 例(60%)患者出现 4 级 HC。无术中并发症。术后有 6 例患者发生并发症:3 例需要输血,3 例需要静脉内抗生素治疗。导尿管拔除的中位时间为 6 天(IQR 2-10)。中位住院时间为 35 天(IQR 6-73)。术后 30 天,1 例 4 级血尿患者重新定位三通导管,6 例患者完全缓解,3 例部分缓解。
我们的初步经验表明,富含血小板的血浆腔内给药可作为 HSCT 后 BK 诱导的 HC 的一种可行且安全的选择。需要进一步的研究来评估其在其他形式的出血性膀胱炎中的潜在价值。